Extra-renal sources of 1, 25-dihydroxyvitamin D can be increased to normal serum 1, 25-dihydroxyvitamin D levels in chronic kidney disease patients after administration of high dose 25-hydroxyvitamin D. The investigators observed that 1, 25-dihydroxyvitamin D concentrations were significantly increased after 3 months of omega-3 FA supplementation compared to baseline levels without 25-hydroxyvitamin D administration in dialysis patients. In this study, the investigators hypothesized that omega-3 FA and 25-hydroxyvitamin D supplementations may increase 1, 25-dihydroxyvitamin D concentrations much more compared to 25-hydroxyvitamin D supplementation only in hemodialysis patients with insufficient or deficient 25-hydroxyvitamin D levels.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
17
Omega-3 fatty acid ethylester 90, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
Olive oil, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
if baseline 25-hydroxyvitamin D levels are \< 15 ng/mL : 10,000IU/week, if baseline 25-hydroxyvitamin D levels are 16-30 ng/mL : 50,000IU/week, Duration : 12 weeks
Won Suk An
Busan, South Korea
25-hydroxyvitamin D Levels at 12 Weeks
Time frame: 12 weeks
Hemoglobin Levels at 12 Weeks
Time frame: 12 weeks
Changes of Calcium Levels
Time frame: 4 weeks, 8 weeks and 12 weeks
Change of Intact Parathyroid Hormone
Time frame: 12 weeks
Change of Fetuin-A Levels
Time frame: 12 weeks
Change of FGF-23 Levels
Time frame: 12 weeks
Changes of Phosphorous Levels
Time frame: 4 weeks, 8 weeks and 12 weeks
Changes of Erythropoietin Doses
Time frame: 4 weeks, 8 weeks and 12 weeks
Changes of Phosphate Binder Doses
Time frame: 4 weeks, 8 weeks and 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.